The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1002
June 6, 1997
View Complete Issue         Table of Contents 2019 
Brimonidine - An Alpha2-Agonist for Glaucoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Brimonidine - An Alpha2-Agonist for Glaucoma
June 6, 1997 (Issue: 1002)
Brimonidine tartrate 0.2% ophthalmic solution (Alphagan - Allergan), a selective alpha2-adrenergic agonist, has been approved by the US Food and Drug Administration (FDA) for treatment of increased intraocular pressure due to open-angle glaucoma ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Brimonidine - An Alpha2-Agonist for Glaucoma
Article code: 1002b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.